Drug Trial Radar · NCT06717269
A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
223
Actual
Start
Nov 30, 2024
Primary completion
May 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- Nurix Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
Conditions
- Healthy Volunteer
Interventions
NX-5948Drug
Administered orally in tablet or capsule form
EsomeprazoleDrug
Administered orally in capsule form
PlaceboDrug
Administered orally matching NX-5948 tablets
FamotidineDrug
Administered orally in tablet form
MidazolamDrug
Administered orally in syrup form
DigoxinDrug
Administered orally in tablet form
RosuvastatinDrug
Administered orally in tablet form
QuinidineDrug
Administered orally in tablet form
NX-5948Drug
Administered in capsule form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948Time frame: 9 weeks
- Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948Time frame: 9 weeks
- Maximum observed concentration (Cmax): NX-5948Time frame: 9 weeks
- AUC0-t: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
- AUC0-inf: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
- Cmax: Midazolam, rosuvastatin, or digoxinTime frame: 9 weeks
- Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogramTime frame: Baseline, 9 weeks
- Number of participants with treatment-emergent adverse eventsTime frame: Up to 10 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Phoenix, Arizona
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.